A suspicious biopsy report sits in the grey zone between clearly benign and confirmed cancer. It means the pathologist saw cells that look abnormal, enough to raise a flag, but not enough to call it cancer with certainty. So it isn’t a diagnosis. It’s a signal that more is needed, usually further testing or a repeat sample, before anyone can say for sure either way.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “A suspicious report isn’t bad news or good news yet, it’s a call to investigate properly, and I’d far rather act on a careful follow-up than treat or dismiss something on a guess.”

A few different things land a report in that uncertain middle. Here’s what’s usually behind it.

• Too few cells: When the sample is sparse or poorly preserved, the pathologist can see something’s off but doesn’t have enough to commit to a verdict.
• Borderline appearance: Some cells sit right between normal and malignant, showing early changes that could go either way without more information.
• Overlapping features: Certain benign conditions mimic cancer closely under the microscope, and telling them apart often needs more than a first look.
• Sampling spot: If the needle caught the edge rather than the core of a lump, the most telling cells may simply not be in the sample.

So “suspicious” often says more about the sample than the disease. Anyone heading toward robotic cancer surgery needs that uncertainty resolved first, not carried into the operating room.

The report isn’t the finish line, it’s a prompt for the next step. This is what usually follows.

• Special staining: Pathologists apply molecular tests that tag specific proteins, turning a borderline read into a much clearer answer about the cell type.
• Repeat biopsy: Sometimes the simplest fix is a fresh sample, ideally a core biopsy that pulls more tissue than the first attempt managed.
• Expert review: A second pathologist, often a specialist in that cancer type, can settle a difficult case that one reading left open.
• Clinical correlation: The result gets weighed against your scans and symptoms, because a report never stands entirely on its own.

So uncertainty is temporary, not permanent. Much like what an IHC test adds to the picture, the next test is what turns “suspicious” into something you can actually act on.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery. He’s spent much of that time in exactly these diagnostic grey zones, where a report and a clinical picture don’t quite line up and someone has to decide the next move.

And that judgment is what keeps a suspicious report from becoming either overtreatment or a missed cancer. Every case at MACS Clinic runs through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. 1. 1. National Cancer Institute — Pathology Reports. https://www.cancer.gov/
      2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

FNAC is surprisingly accurate for what it is, a thin needle drawing a few cells from a lump. In experienced hands it gets the answer right well over ninety percent of the time for many cancers, especially in the thyroid, breast and lymph nodes. It isn’t flawless though, and when the result is unclear or the sample’s too thin, a core biopsy usually takes over to settle it.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I trust FNAC for a thyroid or lymph node lump, but I never let a single negative result overrule a lump that looks and feels like cancer, that’s when I push straight to a core biopsy.”

Accuracy isn’t fixed. It swings a lot depending on a few things going right.

• Who does it: A skilled hand placing the needle in the right spot changes everything, since a sample drawn from the edge of a lump can miss the cancer entirely.
• Cell quality: The pathologist needs enough clear cells to judge, and a sparse or bloody sample is where false negatives tend to creep in.
• Cancer type: Some tumours shed cells that read easily, while others, like certain follicular thyroid cancers, simply can’t be confirmed by cells alone.
• The lump itself: Tiny, deep or hard-to-reach lumps are harder to sample cleanly, which is exactly when accuracy starts to dip.

So a “negative” FNAC isn’t always the end of it. Anyone weighing up robotic cancer surgery wants that diagnosis nailed down first, not left on a borderline result.

Sometimes cells alone don’t cut it. Here’s when your doctor reaches for the next test.

• Unclear result: If the FNAC comes back inconclusive or suspicious rather than definite, a core biopsy gives the tissue needed to be sure.
• Architecture matters: FNAC shows cells, not how they’re arranged, and for some cancers that arrangement is what confirms the type.
• Planning treatment: Detailed tests like hormone receptors or molecular markers often need a tissue sample, which FNAC can’t always provide.
• Result and clinic clash: When a clean FNAC sits next to a worrying lump or scan, that mismatch is a clear signal to dig deeper.

So FNAC and tissue testing aren’t rivals, they work in sequence. Much like the choice explained in our core biopsy comparison, it’s about matching the test to what the case actually needs.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery. He reads an FNAC report the way a surgeon has to, never in isolation, always against the lump, the scans and the bigger clinical picture.

And that’s what stops a borderline result from becoming a wrong turn. Every case at MACS Clinic runs through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Fine Needle Aspiration. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

A doctor orders a PET scan after a CT because the two tests answer different questions. A CT shows the size, shape and location of a mass, while a PET reveals how metabolically active that tissue actually is. Cancer cells burn glucose fast, so they light up on a PET in a way a CT simply can’t show. Together they confirm whether the disease is active and how far it has spread.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “A CT tells me what a lump looks like, but a PET tells me whether it’s behaving like cancer, and that difference often decides the whole treatment plan.”

A CT maps anatomy. A PET maps activity. That gap is the entire reason both get used.

• Cell activity: PET picks up the high glucose uptake of cancer cells, so it flags disease that’s biologically active rather than just a shadow on an image.
• Hidden spread: Small deposits in lymph nodes or distant organs often stay invisible on CT, and PET catches many of them before they grow large enough to see.
• Scar vs cancer: After treatment, a CT can show a lingering mass that’s only scar tissue, and PET tells whether it’s dead or still alive.
• Whole body: One PET scan surveys the entire body at once, which matters when the worry is spread rather than a single known site.

So the two aren’t rivals. A patient working through their cancer staging gets a far more complete picture when structure and activity are read side by side.

Not every case needs one. But in specific situations a PET changes the decision entirely.

• Staging: When a cancer is confirmed, PET helps pin the true stage by checking whether it has quietly travelled beyond the primary site.
• Unclear findings: If a CT shows something borderline that could go either way, PET often settles whether it’s worth a biopsy or surgery.
• Treatment response: Midway through chemo or radiation, PET shows whether the tumour is genuinely shrinking in activity, not just in size.
• Suspected recurrence: When markers rise but a CT looks clean, PET can locate disease that’s returned before anything else picks it up.

So the timing isn’t random. Much like getting a second opinion, the extra scan is about confirming the picture before committing to a plan.

Dr. Sandeep Nayak holds a DNB in Surgical Oncology and General Surgery, with 24 years in the field and a practice built entirely around cancer. He reads imaging the way a surgeon has to, looking not just at what a scan shows but at what it means for whether, when and how to operate.

For a patient, that’s the difference between a scan report and a plan. Every case at MACS Clinic goes through a full tumour board, where imaging, pathology and oncology are weighed together before anything is confirmed. Reach the team at 📞 +91 9482202240.

References:

1. National Cancer Institute — PET Scans. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Robotic surgery is becoming the future of cancer treatment because it gives the surgeon precision, magnified vision and reach that open and laparoscopic methods can’t match consistently. Tumours come out through small incisions, with nerves and healthy tissue left intact, so pain drops and recovery speeds up. And for many solid tumours, the outcome data already leans this way.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Robotic surgery lets us operate in spaces the human hand can’t reach cleanly, and that control is exactly what changes a difficult cancer case into a safe one.”

The edge isn’t the machine itself. It’s what the surgeon can suddenly do.

• 3D vision: The surgeon works from a magnified high-definition 3D view, not the flat 2D image laparoscopy offers, so depth and tissue planes stay clear right through the operation.
• Motion control: Instrument movement scales down to a fraction of the hand’s motion, which settles natural tremor and makes fine dissection possible in tight, awkward spots.
• Nerve sparing: Veins and nerves show up enlarged and far easier to spot, and that’s decisive in rectal, prostate and gynaecologic surgery where preserving them matters.
• Smaller wounds: A few sub-centimetre cuts replace one long incision, so blood loss falls and patients are back on their feet much sooner.

And those gains stack up. Anyone weighing robotic cancer surgery should look at the surgeon’s experience just as hard as the technology.

Not every tumour needs it. But several are a genuinely strong fit.

• Prostate cancer: The gland sits deep in the pelvis, surrounded by nerves that control continence and potency, and robotic access protects them more reliably than open surgery does.
• Colorectal cancer: These cases are technically tough, and nerve-sparing robotic technique helps preserve bladder, bowel and sexual function wherever the disease allows.
• Gynaecologic cancers: Ovarian, cervical and uterine tumours sit in cramped pelvic anatomy, and the wristed instruments reach angles rigid laparoscopic tools simply can’t.
• Head and neck cancer: Transoral robotic surgery reaches throat tumours through the mouth, so there’s no cut across the face or jaw and recovery is gentler.

So the real question isn’t whether the technology looks impressive. It’s whether your specific cancer is one where it actually changes the result. Our blog on robotic cancer surgery costs breaks down when it’s worth it.

Dr. Sandeep Nayak trained overseas specifically to master laparoscopic and robotic onco-surgery, holds a DNB in Surgical Oncology and General Surgery, and has performed hundreds of robotic cancer procedures across 24 years in the field. He’s also the originator of three published techniques, RABIT, MIND and RIA-MIND, which surgeons now travel to learn.

For a patient, what that adds up to is simple. You aren’t getting someone who tries robotics now and then. You’re getting one of the most experienced robotic cancer surgeons in the country, with every case run past a full tumour board before anything gets confirmed. Reach the team at 📞 +91 9482202240.

References

1. National Cancer Institute — Robotic Surgery. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Open, laparoscopic and robotic are three surgical approaches and none of them is universally better than the other two. Open surgery suits complex locally advanced tumours where direct access changes what is safely achievable. Laparoscopic cuts recovery time for appropriate stages without compromising cancer control. Robotic adds wristed instrument precision in tight spaces like the pelvis and neck where standard laparoscopic tools fall short. Your cancer type, tumour location and the surgeon’s specific volume with that technique determine which one actually fits your case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The best surgical approach for cancer is the one that achieves complete tumour removal with the best functional outcome for that specific patient, not the most advanced-sounding option available.”

Each approach suits a different clinical situation. Here is what actually separates them:

• Open Surgery: A large incision gives direct hands-on access to the tumour and surrounding structures, making it the right call for locally advanced cancers, vascular involvement or cases where intraoperative findings demand immediate unplanned decisions.
• Laparoscopic Surgery: Small incisions with a camera and long instruments reduce blood loss, hospital stay and recovery time while producing equivalent cancer control to open surgery for appropriate stage and tumour location.
• Robotic Surgery: The da Vinci system adds a 3D magnified view and wristed instruments that change what is achievable in confined spaces like the pelvis, neck and retroperitoneum where standard laparoscopic instruments simply cannot replicate the same precision.
• How the Decision Gets Made: Tumour location, disease extent, patient fitness and the surgeon’s specific volume with that technique for that cancer type all determine the right answer, not a general preference for one approach over another.

The right approach is matched to the case not to what the centre finds most convenient. Patients in Bangalore exploring their options should ask specifically about surgeon volume before deciding. Laparoscopic cancer surgery at MACS Clinic covers the full spectrum where every approach decision starts from what your case actually needs.

The right approach depends on specific clinical factors. Here is when each one genuinely fits:

• Open Surgery Fits When: Locally advanced tumours with vascular involvement, dense adhesions from prior surgery or emergency presentations where speed and direct access outweigh the recovery benefits of minimally invasive access.
• Laparoscopic Fits When: Early to intermediate stage colorectal, gastric, kidney and gynaecological cancers where tumour size and location allow safe port placement and the evidence base for oncological equivalence is well established.
• Robotic Fits When: Low rectal cancer needing sphincter preservation, thyroid cancer where RABIT scarless access applies, prostate cancer and pelvic or neck cancers where wristed instruments in a confined space produce functional outcomes that open and standard laparoscopic surgery cannot consistently match.
• When the Approach Should Change: Unexpected intraoperative findings that reveal disease extent requiring open access mean conversion is the right clinical call, not a failure, and a surgeon’s willingness to make that decision honestly tells you more about their judgment than their technique preference.

The right surgical approach for your specific cancer needs your staging scans and a surgeon honest enough to recommend what actually serves your case. Robotic cancer surgery at MACS Clinic covers the full robotic oncology spectrum including RABIT, MIND and RIA-MIND where robotic precision changes what is clinically achievable.

Prof. Dr. Sandeep Nayak performs open, laparoscopic and robotic cancer surgery across colorectal, thyroid, head and neck, ovarian and gastric cancers at MACS Clinic, which means the approach recommended for your case is genuinely matched to what it needs rather than what the centre does most. He developed RABIT for scarless thyroid surgery and MIND and RIA-MIND for robotic pelvic cancer surgery, performed over a thousand minimally invasive cancer procedures and brings 24 years of surgical oncology experience to every case. Every surgical approach decision goes through full tumour board review before anything is confirmed, reach the team at 📞 +91 9482202240.

Reference Links:

1. 1. National Cancer Institute — Surgery to Treat Cancer. https://www.cancer.gov/about-cancer/treatment/types/surgery
   2. American Cancer Society — Surgery for Cancer. https://www.cancer.org/cancer/managing-cancer/treatment-types/surgery.html